STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years

STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing^® coronary stent, today announces that three-year follow-up imaging data from the STENTYS arm of the APPOSITION IV clinical study confirms the long-term performance of the sirolimus-eluting Self-Apposing stent. The data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA.

The data were obtained by Quantitative Coronary Angiography (QCA) and Optical Coherence Tomography (OCT) from a group of patients that were examined three years post-treatment for ST-elevation Myocardial Infarction with the STENTYS stent. The in-stent Late Lumen Loss was 0.08mm (±0.43), while the rate of well-apposed struts was 99.3% and the rate of strut covered by tissue was 99.7%.

Robert-Jan van Geuns, M.D., Ph.D., from Erasmus Medical Center (Rotterdam, the Netherlands), who will present these results today at TCT, said: "These images reinforce our confidence that the STENTYS Sirolimus-eluting stent performs very well, not only in the short-term, as previously demonstrated, but also at a much later time point.”

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, stated: "We expect that these exciting long-term results for our Sirolimus-eluting Self-Apposing stent, which is now commercially available in Europe with a new balloon delivery system under the brand Xposition^®, will further drive adoption as cardiologists recognize the potential to optimally treat their patients without the risk of severe malapposition observed with conventional stents.”

To read the complete presse release, please click here.

STENTYS is listed on Comp. C of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT

View source version on businesswire.com: http://www.businesswire.com/news/home/20151012005968/en/